![Ray Lockard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ray Lockard
Corporate Officer/Principal chez
TSCAN THERAPEUTICS, INC.
Profil
Ray Lockard is currently Chief Manufacturing & Quality Officer at TScan Therapeutics, Inc., starting in 2026.
Formerly, Mr. Lockard was Executive Director-CMC, QA & External Quality at Ultragenyx Pharmaceutical, Inc. from 2020 to 2021 and Head-Site Quality at Novartis Gene Therapies, Inc. from 2019 to 2020.
Education includes an undergraduate degree from Hampden-Sydney College and an MBA from Kenan-Flagler Business School.
Postes actifs de Ray Lockard
| Sociétés | Poste | Début |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2024 |
Anciens postes connus de Ray Lockard
| Sociétés | Poste | Fin |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/12/2021 |
| AVEXIS INC | Corporate Officer/Principal | 01/10/2020 |
Formation de Ray Lockard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
43
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Hampden-Sydney College
 Hampden-Sydney College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kenan-Flagler Business School
 Kenan-Flagler Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
